• Fivot

  Participated · Series B · Nov 2025

  Founded in 2019, Fivot aims to reinvent corporate and personal finance in Japan by operating two complementary businesses: the venture-debt platform Flex Capital and the Visa-branded cashless savings app IDARE. Flex Capital offers non-dilutive funding through venture debt, revenue-based financing and invoice-advance products, underpinned by a proprietary, AI-powered credit-scoring model. The service has originated more than ¥120 billion in loans to over 300 startups while maintaining a low default rate in the 0.3 % range. IDARE incentivizes users with a 2 % annual-equivalent bonus on balances and personalized, AI-based saving features, helping individuals build wealth while feeding liquidity back into Flex Capital’s lending pool. With fresh capital, the company plans to deepen AI research, refine its credit algorithms, scale marketing for both products and expand its lending reach to a broader set of SMEs. Cumulative equity financing now totals ¥25 billion, giving Fivot additional resources to pursue its vision of becoming a full-fledged challenger bank.

• SDP Japan

  Participated · Series D · Jun 2025

  SDP Japan develops integrated surgical-care platforms that help partner medical institutions with patient acquisition, supply procurement, real estate and medical equipment sourcing, and administrative operations. The company focuses on establishing and expanding specialty surgical institutions in orthopedics and cardiovascular care, primarily having produced seven surgery-focused facilities in the Tokyo metropolitan area. Its supported facilities performed over 3,000 surgeries in 2024, bringing cumulative procedures to approximately 14,000, and rank third in Tokyo for arrhythmia and hip joint replacement volumes. SDP Japan positions its model as a Japan-specific analogue to ASCs/HOPDs used internationally, aiming to realign acute care within Japan’s public insurance system. The company plans to use the new capital to strengthen its growth platform, roll out advanced surgical-care models nationwide, and rebuild medical infrastructure in regional cities to reduce disparities in access to care. The business case is supported by demographic trends: rising surgical demand in orthopedics and cardiovascular specialties (projected 5–8% annual growth) driven by Japan’s super-aging society.

• Zpeer

  Participated · Equity · May 2024

  Zpeer develops digital platforms and products to support clinical veterinarians, animal hospitals, and pet owners. Its services include the specialist media 'ベットピア' (with ~13,000 registered clinical veterinarians, about 80% of the market) and the EC site 'アニマート' (with ~3,000 registered animal hospitals), plus the webinar platform 'VetScope'. The company also sources and sells innovative functional products for animals that previously were not available domestically. Zpeer plans to strengthen its digital platform, invest in advanced services and products that contribute to veterinary medicine, and reinforce its talent and operational foundation. Financially, it has been scaling via equity and borrowings, using capital to accelerate platform-led growth.

• Mepple

  Led · Series A · Nov 2023

  Mepple produces KOREDAKE, a 100% plant‑based soy wellness protein formulated as a complete nutrition meal with 33 nutrients (including 26 vitamins/minerals), 22g+ protein and high fiber per serving. Launched in March 2020, the product has grown primarily via word‑of‑mouth and direct subscriptions, with over 20,000 members, more than 95% of purchases on the company site coming from repeat subscriptions, and a continuation rate above 93%. The brand offers multiple flavors, a shaker‑free single‑serve “Shake Pack,” and emphasizes taste, solubility and sustainability (botanical‑ink packaging, bamboo spoons, plant‑based ingredients). KOREDAKE won a Good Design Award and a Pentawards gold in 2022. Mepple plans to use new capital to strengthen marketing and awareness, develop new products, improve its subscription service, and advance sustainability and public‑interest initiatives including pursuing B Corp certification. The company is headquartered in Shibuya, Tokyo and was founded on January 11, 2018.

• Curreio

  Participated · Series A · Mar 2023

  Curreio is a biotechnology company that provides Cryo‑Electron Microscopy (Cryo‑EM) structural‑analysis technology to accelerate drug discovery. The company determines high‑resolution structures of disease target proteins and ligand complexes, with particular strength on integral membrane protein families. Over the past three years Curreio has worked on more than 20 protein targets and solved structures for over 80% of them; roughly 70% of targets were integral membrane proteins. It integrates Cryo‑EM outputs with AI‑driven computational chemistry to increase hit rates while lowering R&D time and cost, and currently has four ongoing R&D projects. The team reports having extended its platform to analyze lower‑molecular‑weight targets (approximately 60 kDa) with ligands (publication in preparation). Curreio plans to use recent financing to further accelerate R&D programs and broaden its Cryo‑EM platform applicability.

No current team members are available.